This website is intended for healthcare professionals only.
EXPLORING LONG-TERM TREATMENT OUTCOMES IN CCA
Dr. Mohammed Alghamdi,
Director of the Oncology center at King Saud University Medical City and Chairman of Saudi Society of GI Oncology
Riyadh, Saudi Arabia
Prof. Teresa Macarulla, Head of the Gastrointestinal Cancer Program Unit Vall d’Hebron University Hospital
Barcelona, Spain
This webinar focuses on long-term outcomes in CCA achieved with 2L targeted treatments. It highlights the importance of early genetic testing in guiding CCA treatment decisions.
Indication: CCA
Key points covered
This webinar covers the following points:
• Targeted treatment shows promise for patients with CCA
• Early genetic testing could help identify patients who could benefit from targeted treatments
• While long-term data for a targeted treatment is scarce, ivosidenib has shown promising long-term PFS and OS, as well as tumor shrinkage, in CCA patients with IDH1 mutations who received ivosidenib for ≥1 year
An interactive clinical case is also presented to illustrate these points
Webinar Replay
Featured Speaker
Prof. Teresa Macarulla
Teresa Macarulla, MD, PhD, is an active member of the European Society for Medical Oncology and the American Society of Clinical Oncology. She is an ad hoc reviewer for various oncology journals. Furthermore, she actively participates in Phase I, II and III studies with new chemotherapy agents in gastrointestinal tumors. She is specialized in translational research on hepatobiliopancreatic tumors and targeted therapies such as EGFR inhibitors.
Dr. Mohammed Alghamdi
Dr. Alghamdi graduated with an MBBS degree from King Saud University – College of Medicine in Riyadh, Saudi Arabia, in 2007. He completed his internal medicine residency at King Khalid University, obtaining certifications in Internal Medicine from both the Saudi and Arab boards, as well as a fellowship from King Saud University. Currently, Dr. Alghamdi holds the position of director of the Oncology Center at King Saud University Medical City and serves as the Chairman of the Saudi Society of GI Oncology since March 2022. His expertise and dedication contribute significantly to the field of oncology in both academic and clinical settings.
